Trivicay
Dolutegravir Maintains Virologic Suppression in Multiple Trials
Dolutegravir-based regimens provide long-term suppression in HIV patients, according to presentations at the 22nd ...
JULY 26, 2018
Good Virologic Response Seen for Bictegravir in HIV
News from CROI 2017: Gilead's novel, investigational drug appears to be promising in rapidly suppressing HIV.
FEBRUARY 15, 2017
New Antiretroviral Drugs Reduce Risk for HIV Transmission
A triple regimen based on an integrase inhibitor decreases viral load in semen very quickly, reducing transmission ...
NOVEMBER 22, 2016
Load more